Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-01-02
2007-01-02
Richter, Johann (Department: 1616)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
Reexamination Certificate
active
10788041
ABSTRACT:
Methods having novel enoxaparin sodium dosing regimens for patients with severe renal impairment are disclosed. The methods may be used for one or more of preventing thrombotic episodes, treating thrombotic episodes, preventing postoperative venous thrombosis, controlling thrombosis and/or decreasing blood hypercoagulation and/or hemorrhaging risks, treating unstable angina, and treating non-Q-wave myocardial infarction in human patients with severe renal impairment. The methods of preventing thrombotic episodes, treating thrombotic episodes, preventing postoperative venous thrombosis, and controling thrombosis and/or decreasing blood hypercoagulation and/or hemorrhaging risks, comprise administering from more than 20 mg to less than 40 mg, from 25 mg to 35 mg, about 30 mg, or 30 mg of enoxaparin sodium to the patient once daily. The methods of treating unstable angina, and non-Q-wave myocardial infarction, comprise administering from more than 0.5 mg/kg body weight to less than 1.5 mg/kg body weight, or about 1 mg/kg body weight of enoxaparin sodium once daily. Articles of manufacture comprising enoxaparin sodium and instructions for the use of the enoxaprin sodium are also disclosed.
REFERENCES:
Drug Facts and Comparisons (56th Ed. 2002), pp. 171-174.
Aghassarian et al., “A Comparative Pharmacodynamic Study of Anti-Xa Activity to Evaluate the Accumulation Effect of Tinzaparin and Enoxaparin Given at Prophylactic Dose Over 8 Days in Medical Elderly Patients with Impaired Renal Function,”Blood, vol. 106(11), pt. 2, p. 118b, Abstract 4152 (Nov. 16, 2005).
Leri et al., “Current Enoxaparin Dosing Strategies Yield Supretherapeutic Anti-Xa Activity in Many Elderly Patients,”Journal of the American College of Cardiology, vol. 43(5), Suppl. A, p. 509A, Abstract 1141-190 (Mar. 3, 2004).
Bacher et al., “Postoperative Monitoring of Low Molecular Weight Heparin Prophylaxis in High-Risk Patients,” Seminars in Thrombosis and Hemostasis, vol. 19, Supp. 1', pp. 73-78 (1993).
Bazinet et al., “Dosage of Enoxaparin Among Obese and Renal Impairment Patients,”Thrombosis Research, vol. 116, pp. 41-50 (2005).
Becker et al., “Excess Body Weight Does Not Adversely Influence Either Bioavailability or Anticoagulant Activity of Enoxaparin Administered Subcutaneously in Acute Coronary Syndromes,” Suppl. to Circulation, 102, pp. II-427-II-428 (2000).
Lopez-Sanchez et al., “Enoxaparin, Retroperitoneal Haematoma in the Elderly and Imparied Renal Function,”Anaesthesia and Intensive Care, vol. 33(5), pp. 689-690, (Oct. 2005). pp. 689-690.
Darius et al., “Antithrombotische Therapie mit Niedermolekularen Heparinen bei Niereninsuffizien,”Journal für kerdiologie: Österreichische Zei, vol. 11(7-8), pp. 313-316 (2004).
Desjardins et al., “Correlation of Plasma Coagulation Parameters With thromboprophylaxis, Patient Characteristics, and Outcome in the MEDENOX Study,”Arch. Pathol. Lab. Med., vol. 128, pp. 519-526, (May 2004). p. 519-526.
Farooq et al., “Serious Adverse Incidents With the Usage of Low Molecular Weight Heparins in Patients With Chronic Kidney Disease,”American Journal of Kidney Diseases, vol. 43(3), pp. 531-537 (Mar. 2004).
Gouin-Thibault et al., “Safety Profile of Different Low-Molecular Weight Heparins Used at Therapeutic Dose,”Drug Safety, vol. 28(4), pp. 333-349 (2005).
Green et al., “Dosing strategy for enoxaparin in patients with rental impairment presenting with acute coronary syndromes,”British Journal of Clinical Pharmacology, vol. 59(3), pp. 281-290 (2004).
Horvitz, M.M. et al., “Enoxaparin injection intervention for patients with severe renal impairment,”Pharm.D, vol. 25(3), p. 481, (Mar. 2005). pp. 481, Abstract 179.
Hulot et al., “Dosing strategy in patients with renal failure receiving enoxaparin for the treatment of non-ST—segment elevation acute coronary syndrome,”Clin. Pharmacol. Ther., vol. 77, pp. 542-552 (2005).
Hulot et al., “Effect of Renal Function on the Pharmacokinetics of Enoxaparin and Consequences on Dose Adjustment,”Ther. Drug Monit., vol. 26(3), pp. 305-310, (Jun. 2004). pp. 305-310.
Jaffer et al., “Prevention of Venous Thromboembolism in the Geriatric Patient,”Clin. Geriatr. Med., vol. 22, pp. 93-111 (2006).
Jones et al., “Pharmacoeconomics of Low-Molecular-Weight Heparins: Limitations of Studies Comparing Them to Unfractionated Heparin”,Expert Opin. Pharmacother., vol. 5(9), pp. 1887-1897 (Sep. 2004).
Kruse et al., “Retrospective evaluation of a pharmacokinetic program for adjusting enoxaparin in renal impairment,”American Heart Journal, vol. 148(4), pp. 582-589, (Oct. 2004), pp. 582-589.
Nagge and Huh, Letter to the Editor,Am Heart J, 149:e21 (2005).
Uthamalingam et al., “Enoxaparin-Associated Spontaneous Retroperitoneal Hematoma in Elderly Patients With Impaired Creatinine Clearance: A Report of Two Cases,”JAGS, vol. 52(3), pp. 477-479, (Mar. 2004).
Conde-Martel et al., “Spontaneous Retroperitoneal Hematomas in Elderly Patients Treated With Low-Molecular-Weight Heparins,”JAGS, vol. 53(3), pp. 548-549, (Mar. 2005).
Liboux et al., “Enoxaprin Pharmokinetics and Pharmacodynamics After Intravenous Bolus Administration Alone and at Initiation of a Subcutaneous Dosing Regimen,”Journal of the American College of Cardiology, Abstract 1106-129, p. 373A, Abstract 1106-129 (2000).
Lojewski et al., “Evaluation of Hemostatic and Fibrinolytic Alterations Associated with Daily Administration of Low-Molecular-Weight Heparin for a 12-Week Period,”Seminars in Thrombosis and Hemostasis, vol. 21 (2), pp. 228-239 (1995).
Ma et al., “Anti-Xa Monitoring of Enoxaparin for Acute Coronary Syndromes in Patients with Renal Disease,”The Annals of Pharmacotherapy, vol. 38, pp. 1576-1581, (Oct. 2004). pp. 1576-1581.
Macie et al., “Dosing Practices and Risk Factors for Bleeding in Patients Receiving Enoxaparin for the Treatment of an Acute Coronary Syndrome,”CHEST, vol. 125 (5), pp. 1616-1621 (2004).
Martin, J. L, “Reliable Anticoagulation with Enoxaparin in Patients Undergoing Percutaneous Coronary Intervention: Final PEPCI Trial Results,”The American Journal of Cardiology, Abstract TCT-409, pp. 158H-159H (2002).
Martin et al., “Reliable Anticoagulation With Enoxaparin in Patients Undergoing Percutaneous Conorary Intervention: The Pharmacokinetics of Enoxaparin in PCI (PEPCI) Study,”Catheterization and Cardiovascular Interventions, vol. 61, pp. 163-170 (2004).
Peng et al., “Renal Function, Peak Anti-Xa Levels and Enoxaparin Dosing,”Journal of Pharmacy Practice and Research, vol. 34(1), pp. 14-17, (2004). pp. 14-17.
Product Monograph, Lovenox, Aventis Pharma Inc., and Notice of Compliance, Feb. 28, 2003.
Reply to the Letter to the Editor,Am. Heart J., 149:e23-e-24, (Mar. 2005).
“Heparin Contraindicated in Severe Renal Impairment,”WHO Drug Information, vol. 19(1), pp. 24-25, (2005).
Sanderink et al., “Enoxaparin Pharmacokinetics and Pharmacodynamics in Renal Impairment,”Journal of the American College of Cardiology, 37(2), Abstract 1076-169, p. 229-A (2001).
Siguret et al.,“Low molecular weight heparin treatment in elderly subjects with or without renal insufficiency: new insights between Jun. 2002 and Mar. 2004,”Curr. Opin. Pulm. Med., vol. 10, pp. 366-370 (2004).
Thorevska et al., “Anticoagulation in Hospitalized Patients With Renal Insufficiency, A Comparison of Bleeding Rates With Unfractionated Heparin vs Enoxaparin,”CHEST, vol. 125(3), pp. 856-863, (Mar. 2004).
Abdel-Raheem, Majdi M., et al., “Effect of Low-Molecular -Weight Heparin on Potassium Homeostasis,”Pathophysiology of Haemostasis and Thrombosis, vol. 32, pp. 107-110 (2002).
Alikhan, Raza, et al., “Prevention of Venous Thromboembolism in Medical Patients with Enoxaparin: A Subgroup Analys
Bacher Hans Peter
Sanderink Ger-Jan C. M.
Vetticaden Santosh
Aventis Pharma S.A.
Aventis Pharmaceuticals Inc.
Choi Frank I
Finnegan Henderson Farabow Garrett & Dunner L.L.P.
Richter Johann
LandOfFree
Administration of enoxaparin sodium to patients with severe... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Administration of enoxaparin sodium to patients with severe..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Administration of enoxaparin sodium to patients with severe... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3748740